Aberrant B-cell function, which could arise from various underlying causes, is central to the pathogenesis of diverse ...
AstraZeneca has recently been investing heavily in the cell therapy space, including two acquisitions for TeneoTwo and ...
Explore diffuse large B-cell lymphoma — symptoms, causes, diagnosis, treatment options, and prevention. Learn about its types ...
MS patients on anti-CD20 therapies are significantly less likely to discontinue treatment than those given other DMTs, a ...
A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the long-term, drug-free ...
Zacks Small Cap Research on MSN1d
INAB: Introducing INB-600, A γδ T Cell Engager PlatformINAB READ THE FULL INAB RESEARCH REPORT Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc ...
Fred Locke, MD, Moffitt Cancer Center, explains why this hematologic cancer is such an attractive target for chimeric antigen ...
The following is a summary of “Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With ...
A study on the long-term safety of CAR T-cell therapy for B-cell lymphoma patients reveals a favourable safety profile with ...
India's gene therapy for blood cancers shows 73% response rate, offering hope and cost-effective treatment for patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback